Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–89 of 89 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Diskus Clear all

Conditions: Asthma
Interventions: Vilanterol, Salmeterol Inhalation Powder, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder Diskus; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Huntington Beach, California • Orlando, Florida • Tallahassee, Florida + 8 more

Conditions: Asthma, Bronchial Diseases, Respiratory Tract Infections, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Immune System Diseases
Interventions: Asthma Symptom Monitoring online tools, Inhaled Steroids, Azithromycin Pill; Other · Drug
Lead sponsor: DARTNet Institute; Government
Eligibility: 12 Years to 75 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Asthma, COPD
Interventions: MGR001, Advair® Diskus®, Seretide™ Accuhaler™; Drug
Lead sponsor: Mylan Pharma UK Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 16
States / cities: Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more

Conditions: Asthma
Interventions: Placebo, FP 100mcg, FP 500mcg, FP 250mcg, FSC 100/50mcg, FSC 250/50mcg, FSC 500/50mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Asthma
Interventions: Fluticasone propionate/salmeterol, Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder, Placebo; Drug
Lead sponsor: West-Ward Pharmaceutical; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Asthma
Interventions: fluticasone; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 12 Years to 69 Years
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 13
States / cities: San Diego, California • Jacksonville, Florida • Miami, Florida + 10 more

Conditions: Asthma
Interventions: FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 38
States / cities: Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more

Conditions: Asthma, Seasonal Allergic Rhinitis
Interventions: Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID; Drug
Lead sponsor: Creighton University; Other
Eligibility: 15 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions: Fluticasone propionate/salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 51
States / cities: Jonesboro, Arkansas • East Artesia, California • Huntington Beach, California + 45 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Propionate/Salmeterol Combination Product, Salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 95
States / cities: Jasper, Alabama • Mobile, Alabama • Glendale, Arizona + 88 more

Conditions: Asthma
Interventions: Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 71
States / cities: Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more

Conditions: Asthma
Interventions: Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Fluticasone Propionate Inhalation Powder, Placebo Inhalation Powder 1, Placebo Inhalation Powder 2; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more

Conditions: Asthma
Interventions: Placebo, FP 100mcg, FP 250mcg, FP 500mcg, FSC 100/50mcg, FSC 250/50mcg, FSC500/50mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 51
States / cities: Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 43 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 6,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 190
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 152 more

Conditions: Asthma
Interventions: Meducation device technique video, Nutrition video; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 8 Years to 16 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Thomasville, North Carolina

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol, Fluticasone Propionate/Salmeterol Combination Product; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 85
States / cities: Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 78 more

Search by objective public record fields.

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

Individualizing Treatment for Asthma in Primary Care

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

GSK BHR Study (Sont)

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

MethaCholine Bronchoprovocation Study (MeCIS)

Fall Epidemic Viral Pediatric Study

Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Efficacy and Safety of Different Doses of Indacaterol

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

GSK BHR Study (Sont - Second Study)

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

ENLaCE Pilot Study

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.